Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Active, not recruiting · Phase 3 · NCT01272037
Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
At a glance
- Research payments reported, 2025
- $5,131
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 5,018
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Anastrozole (drug), Exemestane (drug), Laboratory Biomarker Analysis (other), Letrozole (drug), Quality-of-Life Assessment (other), Systemic Chemotherapy (drug), Tamoxifen Citrate (drug)
- Dates
- Started 2011-02-28; completion 2027-01-08
- Results posted
- Yes
This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in the breast to surrounding normal tissue (invasive). Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killi…
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Menarini Silicon Biosystems, Inc. reported $5,131 in research payments for this study in 2025 (7 payments).
Products named: Cellsearch
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.